Safety & efficacy of Symbicort® Turbuhaler® (1, 2, and 4 x 160/4.5 µg twice daily) in Japanese patients with asthma
Study identifier:D5890C00009
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
An open, phase III, multicentre, 52-week study, evaluating the safety and efficacy of Symbicort® Turbuhaler® (1, 2, and 4 x 160/4.5 µg twice daily) in Japanese patients with asthma
Medical condition
asthma
Phase
Phase 3
Healthy volunteers
No
Study drug
Budesonide/Formoterol
Sex
All
Actual Enrollment
120
Study type
Interventional
Age
16 Years +
Date
Study Start Date: 01 Nov 2005
Primary Completion Date: 01 Dec 2006
Study Completion Date: 01 Jun 2007
Study design
Allocation: Non-randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Investigators
Principal Investigator
AstraZeneca Symbicort Medical Science Director
AstraZeneca
